Cancer name Triple Negative Breast Cancer
Cancer Type BRCA
Immunotherapy type Immune Checkpoint Therapy
Treatment α-PD-1
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Pathway
Signature Ras-MAPK pathway
Official Symbol NA
Mode of action PATH_NR_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description These data suggest that MEK activation can promote resistance to PD-L1 targeted therapy and also support clinical trials testing the combination in patients with TNBC or HER2+ breast cancer, particularly in cases with reduced TILs. Importantly, similar results were achieved with different MEK inhibitors (trametinib or selumetinib) and PD-1 pathway inhibitors (α-PD-L1 or α-PD-1) strengthening conclusions based on pathway-specific effects of these agents.
PMID 26515496
Title RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.